Holen Sie sich die Stockscreener-App
2.17
0.46%
-0.01
Schlusskurs vom Vortag:
$2.18
Offen:
$2.16
24-Stunden-Volumen:
17,509
Relative Volume:
0.25
Marktkapitalisierung:
$102.23M
Einnahmen:
$18.11M
Nettoeinkommen (Verlust:
$-18.95M
KGV:
-4.96
EPS:
-0.4375
Netto-Cashflow:
-
1W Leistung:
+13.02%
1M Leistung:
+14.81%
6M Leistung:
+26.16%
1J Leistung:
-12.15%
1-Tages-Spanne:
$2.16
$2.3108
1-Wochen-Bereich:
$1.86
$2.60
52-Wochen-Spanne:
$1.325
$3.5807
Adagene Inc Adr Stock (ADAG) Company Profile
Vergleichen Sie ADAG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
2.17 | 111.65M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Eingeleitet | China Renaissance | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
Q2 Earnings Forecast for Adagene Issued By Leerink Partnrs - Defense World
Using R and stats models for Adagene Inc. Depositary Receipt forecastingFree AI Forecast for Trending Stocks - Newser
Adagene (NASDAQ:ADAG) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Leerink Partners initiates Adagene stock with Outperform rating on cancer drug potential - Investing.com
What are analysts’ price targets for Adagene Inc. Depositary Receipt in the next 12 monthsAccelerated investment success - Jammu Links News
Why did ADAG's Q4 2020 EPS miss forecasts drastically? - AInvest
Published on: 2025-07-28 00:29:47 - jammulinksnews.com
Adagene Receives FDA Approval for Phase 2 Trial of Muzastotug in MSS CRC - AInvest
Adagene Announces Regulatory Update on Clinical Development - GlobeNewswire
Adagene (NASDAQ:ADAG) Trading Up 3.8% – Should You Buy? - Defense World
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic By Stocktwits - Investing.com India
Adagene advances muzastotug to phase 2 trial after FDA meeting By Investing.com - Investing.com South Africa
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA - MarketScreener
Adagene Advances Clinical Plan for ADG126 in Colorectal Cancer After FDA Meeting - TipRanks
Adagene advances muzastotug to phase 2 trial after FDA meeting - Investing.com
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewswire
Adagene's Cancer Drug Shows Breakthrough 29% Response Rate, FDA Fast-Tracks Phase 2 Trial - Stock Titan
Adagene Inc. and ConjugateBio Inc. Partner to Develop Novel Antibody Drug Conjugate - MarketScreener
Adagene to provide antibody to ConjugateBio for bispecific ADC development By Investing.com - Investing.com South Africa
Adagene Partners With ConjugateBio to Develop ADC Programs - MarketScreener
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewswire
Adagene to provide antibody to ConjugateBio for bispecific ADC development - Investing.com
Adagene Enters $30B ADC Market Through Strategic ConjugateBio Partnership for Novel Cancer Therapeutics - Stock Titan
Adagene Secures $25 Million Investment from Sanofi to Advance Cancer Therapies - TipRanks
Adagene announces up to $25 million strategic investment from Sanofi - GlobeNewswire
Sanofi Bets $25M on Adagene: Strategic Investment, Clinical Trial Deal, and New Cancer Drug Program - Stock Titan
Adagene (NASDAQ:ADAG) Trading 0.3% Higher – Here’s Why - Defense World
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times
Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq
Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan
Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World
Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
New Clinical Data: Adagene's ADG126 Achieves Breakthrough 29% Response Rate in Hard-to-Treat Colorectal Cancer - Stock Titan
ADAGAdagene Inc. Latest Stock News & Market Updates - Stock Titan
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewswire
Biotech Pioneer Behind $25B Alnylam Success Story Takes Strategic Role at Adagene's Cancer Drug Mission - Stock Titan
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Adagene Inc. Announces Poster Presentation on ADG126 at ASCO 2025 Conference - Nasdaq
Adagene Announces Upcoming Poster Presentation on Masked - GlobeNewswire
Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum - The Manila Times
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum - GlobeNewswire
Adagene Reveals New Oncology Strategy: CEO Set for Major Investor Presentation - Stock Titan
FY2025 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World
Adagene (NASDAQ:ADAG) Earns “Buy” Rating from HC Wainwright - Defense World
Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa
Finanzdaten der Adagene Inc Adr-Aktie (ADAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
3.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):